More than one-third of the elevated serum proteins reflected muscle fiber damage and leakage into the bloodstream. A large, reproducible set of blood-based protein biomarkers can reliably distinguish ...

Patients with ATTR-CM who experienced outpatient worsening heart failure had a 2.5-fold increased risk of mortality compared with those who did not. Outpatient worsening heart failure is an ...

Almost all (97%) of the patients with positive planar imaging and positive single-photon emission computed tomography findings were diagnosed with ATTR-CM. Single-photon emission computed tomography ...

Patients reported higher habitual levels of physical activity following the PR intervention, shifting from low to moderate activity levels. A 12-month supervised program of pulmonary rehabilitation ...

Patients with PAH who experience low levels of oxygen may have a poor quality of life, and vital organs may be compromised if these levels are not corrected. 6 Oxygen therapy can help patients ...

Overall, the life expectancy of patients with SCD is lower than that of persons without SCD. 1 However, life expectancy varies depending on the type of disease, treatments administered, and ...

The diagnosis and management of CIDP are complex and best addressed by an interprofessional health care team that includes neurologists, neuromuscular specialists, physical medicine and rehabilitation ...

Between 2001 to 2011, annual age-adjusted incidence increased from 0.55/100,000 to 0.78/100,000, demonstrating an increasing trend with age. Incidence peaks in individuals over 70 years of age ...

The management of PI underwent a transformative shift in 1979 with the US Food and Drug Administration (FDA) approval of intravenous immunoglobulin (IVIg), which became the standard therapy for ...

Individuals with advanced liver disease may also experience significant weight loss due to nausea and poor appetite. Candidates for liver transplantation may need to gain weight to optimize surgical ...

Nipocalimab is currently being evaluated in 2 international randomized studies for HDFN: the UNITY and AZALEA trials. With nearly 1000 times greater affinity for FcRn than intravenous immunoglobulin, ...

(L-R) Rare Disease Advisor senior correspondent Larry Luxner, patient columnists Alithea Athans, Tara Keith and Tom Bartlett, and director of advocacy relations Vera Luxner (Photo by Riya Ajmera) ...